Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.62 |
| ▸ | NPY1R | P25929 | 9/20 | 0.62 |
| ▸ | NPY2R | P49146 | 7/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508501 | 0.95 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL5955065 | 0.95 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508469 | 0.93 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508567 | 0.92 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16507764 | 0.92 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508470 | 0.91 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508438 | 0.91 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL3054631 | 0.90 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508576 | 0.90 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508547 | 0.90 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445636-B2 | Antimicrobial and anticancer lipopeptides | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 2013-05-21 | — | — | US | disclosed |
| US-20100160213-A1 | ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES | YEDA RESEARCH & DEVELOPMENT CO. LTD. | 2010-06-24 | — | — | US | disclosed |
| US-7671011-B2 | Antimicrobial and anticancer lipopeptides | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20070072808-A1 | Antimicrobial and anticancer lipopeptides | YEDA RESEARCH & DEVELOPMENT CO. LTD. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160213-A1 | ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES | VIP, NGLY1, SLC27A1 | NPY4R 2929/4885NPY5R 3482/4885NPY1R 3541/4885 |
| US-20070072808-A1 | Antimicrobial and anticancer lipopeptides | VIP, NGLY1, SLC27A1 | NPY4R 2817/4885NPY5R 3683/4885NPY1R 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.